Home News & Events Press releases Press releases Page tools Share Share Share on FacebookShare on XShare on LinkedinShare on Bluesky Print Search Email Accessibility Category AcquisitionsAwardsCorporate earningsESGInvestor conferencesLeadershipTechnologyWhitepaper Year 2026202520242023202220212020201920182017 In this section In this section Press releases In the News Mediakit Facts and figures ICON spokespeople Awards Events Industry events Webinars Workshops Webinars Social media Connect with us Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media What’s happening in ICON ICON Plc Antibody-drug conjugates (ADCs) continue to reshape global oncology, yet navigating the evolving regulatory landscape remains a significant challenge. In this new BioSpectrum Asia feature, ICON’s regulatory expert, Eili... 13 Mar View post View webpage ICON Plc Antibody-drug conjugates are transforming cancer treatment, but their complexity demands a clear and forward-looking regulatory strategy. In this new BioSpectrum Asia article, ICON experts break down the evolving global... 13 Mar 2 View post View webpage ICON Plc Quality by design and risk based thinking now sit at the centre of modern clinical data science. From digitised protocols to agentic AI, the field is more proactive, connected and patient-focused than ever. In this blog,... 13 Mar 2 View post View webpage ICON Plc Because rare autoimmune conditions are so complex, vaccine decisions should be approached on an individual basis. Discover key elements of a vaccine schedule framework for patients in this vulnerable population in our ne... 13 Mar View post View webpage ICON Plc How to navigate EU MAA Regulations and Registration Regulatory legislation in China differs substantially from that of the European Union. For Chinese biotech companies looking to enter this market it is critical to ass... 12 Mar View post View webpage ICON Plc Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe... 12 Mar View post View webpage ICON Plc Attending #ADPD2026 on 17-21 March? Visit us at booth #29 to learn how ICON is accelerating CNS trials and helping to drive collaboration across advocacy groups, biotech, pharma, and regulators. https://ow.ly/Abvc50Y8Fa0 12 Mar 2 View post View webpage ICON Plc We're pleased to share highlights of our ongoing CSR initiatives in Chennai. Colleagues from ICON's India team recently joined a Plantation Drive at SOS Children's Village, planting over 50 saplings as part of our ongoi... 12 Mar View post ICON Plc On 30 March – 2 April at the World Vaccine Congress, speak with ICON experts at booth 222 to learn how our experience across 180+ vaccine studies, end‑to‑end product development expertise, and fully integrated vaccine‑de... 11 Mar View post View webpage ICON Plc How is AI transforming vaccine‑trial execution? On 31 March at 11:40 am at the World Vaccine Congress, join our interactive working group session, “Vaccine trials: How AI shifts execution from static plans to living sys... 11 Mar View post View webpage ICON Plc Rare autoimmune diseases can leave patients particularly vulnerable to infection, but they often require unique considerations for vaccination. Learn what makes these cases so unique, and what to take into account when b... 11 Mar View post View webpage ICON Plc Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil... 11 Mar View post View webpage
